The authors have declared no conflicts of interest. The patient provided informed consent for the publication of this case report. Acknowledgements: Gupta was involved in writing the original draft, ...

It is used both to treat tumours and to help clinicians determine whether they are cancerous, as well as their grade and ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Perioperative sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) achieved a "promising" clinical complete response ...

Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.

Cancer patients on the Isle of Wight are benefiting from faster treatment and shorter hospital stays. Improvements at St Mary’s Hospital mean patients who previously needed overnight care can now ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

In a trial, ERAS for ambulatory TURBT showed promise for improving early recovery compared with usual care. In a trial, quality of recovery was significantly better for patients receiving an enhanced ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...